Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Breast Neoplasms 3 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Risk Reduction Behavior 1 Patient Preference 1 Patient Acceptance of Health Care 1 Health Behavior 1 Esophageal Neoplasms 1 Diabetes Mellitus 1 Coronary Disease 1 Behavior 1 Barrett Esophagus 1 Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 161 Fluorouracil 135 Paclitaxel 127 Radiotherapy 125 Oxaliplatin 88 Carboplatin 72 Docetaxel 71 Irinotecan 60 pembrolizumab 57 Leucovorin 57 Capecitabine 57 Radiation 48 Esophagectomy 44 Surgical Procedures, Operative 42 Drug Therapy 38 Neoadjuvant Therapy 28 Cetuximab 25 Nivolumab 24 Bevacizumab 21 camrelizumab 20 Trastuzumab 20 S 1 (combination) 19 Chemoradiotherapy 19 Magnetic Resonance Spectroscopy 18 Epirubicin 16 Albumin-Bound Paclitaxel 16 Blood Specimen Collection 15 tislelizumab 14 Taxes 14 Radiotherapy, Intensity-Modulated 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Esophageal Neoplasms × Risk Assessment × Clear all

NCT06306755 2025-01-24

ERSS-EGC

Peking University Cancer Hospital & Institute

Phase NA Recruiting

21,000 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡